Related references
Note: Only part of the references are listed.mTOR-inhibitor treatment of metastatic renal cell carcinoma: contribution of Choi and modified Choi criteria assessed in 2D or 3D to evaluate tumor response
M. Lamuraglia et al.
EUROPEAN RADIOLOGY (2016)
Survival among patients with advanced renal cell carcinoma in the pretargeted versus targeted therapy eras
Pengxiang Li et al.
CANCER MEDICINE (2016)
PET/CT imaging of renal cell carcinoma with 18F-VM4-037: a phase II pilot study
Baris Turkbey et al.
ABDOMINAL RADIOLOGY (2016)
Vascular tumor burden as a new quantitative CT imaging biomarker for predicting metastatic RCC response to antiangiogenic therapy.
Andrew Dennis Smith et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Vascular Tumor Burden as a New Quantitative CT Biomarker for Predicting Metastatic RC Response to Antiangiogenic Therapy
Andrew D. Smith et al.
RADIOLOGY (2016)
Methods and Challenges in Quantitative Imaging Biomarker Development
Richard G. Abramson et al.
ACADEMIC RADIOLOGY (2015)
RECIST 1.1 Compared With RECIST 1.0 in Patients With Advanced Renal Cell Carcinoma Receiving Vascular Endothelial Growth Factor-Targeted Therapy
Katherine M. Krajewski et al.
AMERICAN JOURNAL OF ROENTGENOLOGY (2015)
Cancer Statistics, 2015
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2015)
Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma
T. K. Choueiri et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Metrology Standards for Quantitative Imaging Biomarkers
Daniel C. Sullivan et al.
RADIOLOGY (2015)
FDG and FLT-PET for Early measurement of response to 37.5 mg daily sunitinib therapy in metastatic renal cell carcinoma
Kevin P. Horn et al.
CANCER IMAGING (2015)
ACR Appropriateness Criteria Indeterminate Renal Mass
Marta E. Heilbrun et al.
JOURNAL OF THE AMERICAN COLLEGE OF RADIOLOGY (2015)
89Zr-Bevacizumab PET Visualizes Heterogeneous Tracer Accumulation in Tumor Lesions of Renal Cell Carcinoma Patients and Differential Effects of Antiangiogenic Treatment
Sjoukje F. Oosting et al.
JOURNAL OF NUCLEAR MEDICINE (2015)
Quantitative imaging biomarkers: A review of statistical methods for technical performance assessment
David L. Raunig et al.
STATISTICAL METHODS IN MEDICAL RESEARCH (2015)
Volumetric FDG-PET predicts overall and progression- free survival after 14 days of targeted therapy in metastatic renal cell carcinoma
Jacob Farnebo et al.
BMC CANCER (2014)
Intraobserver and Interobserver Variability in Computed Tomography Size and Attenuation Measurements in Patients With Renal Cell Carcinoma Receiving Antiangiogenic Therapy
Katherine M. Krajewski et al.
CANCER (2014)
Predictive biomarkers in renal cell cancer: Insights in drug resistance mechanisms
Johannes C. van der Mijn et al.
DRUG RESISTANCE UPDATES (2014)
Assessing the Response to Targeted Therapies in Renal Cell Carcinoma: Technical Insights and Practical Considerations
Axel Bex et al.
EUROPEAN UROLOGY (2014)
10% Tumor Diameter Shrinkage on the First Follow-Up Computed Tomography Predicts Clinical Outcome in Patients With Advanced Renal Cell Carcinoma Treated With Angiogenesis Inhibitors: A Follow-Up Validation Study
Katherine M. Krajewski et al.
ONCOLOGIST (2014)
Revised Choi Imaging Criteria Correlate with Clinical Outcomes in Patients with Metastatic Renal Cell Carcinoma Treated with Sunitinib
Yeeliang Thian et al.
RADIOLOGY (2014)
ACR Appropriateness Criteria Post-Treatment Follow-Up of Renal Cell Carcinoma
David D. Casalino et al.
JOURNAL OF THE AMERICAN COLLEGE OF RADIOLOGY (2014)
The role of fluorine-18-fluorodeoxyglucose positron emission tomography in evaluating the response to tyrosine-kinase inhibitors in patients with metastatic primary renal cell carcinoma
Carmelo Caldarella et al.
RADIOLOGY AND ONCOLOGY (2014)
Metastatic Renal Cell Carcinoma: Radiologic Findings and Assessment of Response to Targeted Antiangiogenic Therapy by Using Multidetector CT
Blanca Pano Brufau et al.
RADIOGRAPHICS (2013)
Utilizing pre-therapy clinical schema and initial CT changes to predict progression-free survival in patients with metastatic renal cell carcinoma on VEGF-targeted therapy: A preliminary analysis
Andrew D. Smith et al.
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS (2013)
CT texture analysis using the filtration-histogram method: what do the measurements mean?
Kenneth A. Miles et al.
CANCER IMAGING (2013)
Distribution of metastatic sites in renal cell carcinoma: a population-based analysis
M. Bianchi et al.
ANNALS OF ONCOLOGY (2012)
Standardization of Dynamic Contrast-Enhanced Ultrasound for the Evaluation of Antiangiogenic Therapies The French Multicenter Support for Innovative and Expensive Techniques Study
Nathalie Lassau et al.
INVESTIGATIVE RADIOLOGY (2012)
An update on targeted therapy in metastatic renal cell carcinoma
Giuseppe Lombardi et al.
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS (2012)
Meta-analysis of the diagnostic performance of [18F]FDG-PET and PET/CT in renal cell carcinoma
Hsin-Yi Wang et al.
CANCER IMAGING (2012)
Pharmacodynamic Study Using FLT PET/CT in Patients with Renal Cell Cancer and Other Solid Malignancies Treated with Sunitinib Malate
Glenn Liu et al.
CLINICAL CANCER RESEARCH (2011)
Comparison of Four Early Posttherapy Imaging Changes (EPTIC; RECIST 1.0, Tumor Shrinkage, Computed Tomography Tumor Density, Choi Criteria) in Assessing Outcome to Vascular Endothelial Growth Factor-Targeted Therapy in Patients With Advanced Renal Cell Carcinoma
Katherine M. Krajewski et al.
EUROPEAN UROLOGY (2011)
Targeted Therapies for the Treatment of Metastatic Renal Cell Carcinoma: Clinical Evidence
Thomas E. Hutson
ONCOLOGIST (2011)
Novel Oncologic Drugs: What They Do and How They Affect Images
Roberto Garcia Figueiras et al.
RADIOGRAPHICS (2011)
Assessment of Response to Tyrosine Kinase Inhibitors in Metastatic Renal Cell Cancer: CT Texture as a Predictive Biomarker
Vicky Goh et al.
RADIOLOGY (2011)
Assessing Tumor Response and Detecting Recurrence in Metastatic Renal Cell Carcinoma on Targeted Therapy: Importance of Size and Attenuation on Contrast-Enhanced CT
Andrew Dennis Smith et al.
AMERICAN JOURNAL OF ROENTGENOLOGY (2010)
Morphology, Attenuation, Size, and Structure (MASS) Criteria: Assessing Response and Predicting Clinical Outcome in Metastatic Renal Cell Carcinoma on Antiangiogenic Targeted Therapy
Andrew Dennis Smith et al.
AMERICAN JOURNAL OF ROENTGENOLOGY (2010)
Initial experience with 18F-fluoroethylcholine PET/CT in staging and monitoring therapy response of advanced renal cell carcinoma
Marcus Middendorp et al.
ANNALS OF NUCLEAR MEDICINE (2010)
Impact of maximum Standardized Uptake Value (SUVmax) evaluated by 18-Fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography (18F-FDG-PET/CT) on survival for patients with advanced renal cell carcinoma: a preliminary report
Kazuhiro Namura et al.
BMC CANCER (2010)
Choi response criteria for early prediction of clinical outcome in patients with metastatic renal cell cancer treated with sunitinib
A. A. M. van der Veldt et al.
BRITISH JOURNAL OF CANCER (2010)
CT response assessment combining reduction in both size and arterial phase density correlates with time to progression in metastatic renal cancer patients treated with targeted therapies
Paul D. Nathan et al.
CANCER BIOLOGY & THERAPY (2010)
Metastatic Renal Cell Carcinoma Treated with Sunitinib: Early Evaluation of Treatment Response Using Dynamic Contrast-Enhanced Ultrasonography
Nathalie Lassau et al.
CLINICAL CANCER RESEARCH (2010)
Metastatic Renal Carcinoma: Evaluation of Antiangiogenic Therapy with Dynamic Contrast-enhanced CT
Laure S. Fournier et al.
RADIOLOGY (2010)
Targeted therapies in renal cell cancer: recent developments in imaging
Astrid A. M. van der Veldt et al.
TARGETED ONCOLOGY (2010)
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
E. A. Eisenhauer et al.
EUROPEAN JOURNAL OF CANCER (2009)
Diagnostic and Prognostic Molecular Markers for Renal Cell Carcinoma: A Critical Appraisal of the Current State of Research and Clinical Applicability
Christian Eichelberg et al.
EUROPEAN UROLOGY (2009)
Dynamic contrast-enhanced magnetic resonance imaging pharmacodynamic biomarker study of sorafenib in metastatic renal carcinoma
Olwen M. Hahn et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer
Kathy Miller et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial
Bernard Escudier et al.
LANCET (2007)
Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: Proposal of new computed tomography response criteria
Haesun Choi et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Sorafenib in advanced clear-cell renal-cell carcinoma
Bernard Escudier et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Sunitinib versus interferon alfa in metastatic renal-cell carcinoma
Robert J. Motzer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
To predict progression-free survival and overall survival in metastatic renal cancer treated with sorafenib:: Pilot study using dynamic contrast-enhanced Doppler ultrasound
Michele Lamuraglia et al.
EUROPEAN JOURNAL OF CANCER (2006)
Tumor angiogenesis:: pathophysiology and implications for contrast-enhanced MRI and CT assessment
CA Cuenod et al.
ABDOMINAL IMAGING (2006)
New guidelines to evaluate the response to treatment in solid tumors
F Duffaud et al.
BULLETIN DU CANCER (2000)
New guidelines to evaluate the response to treatment in solid Tumors
P Therasse et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2000)
Share Paper
